The immune system is a collection of internal structures and processes that protects the body from potentially harmful foreign bodies and diseases. It recognizes and distinguishes diverse dangers such as bacteria, viruses, and parasites from the body's healthy tissues. When our immune system becomes weakened and loses its ability to recognize and eliminate aberrant cells, our bodies attack and damage their own tissues, resulting in diseases like cancer and autoimmune diseases. Immunotherapy is a treatment strategy that involves activating, strengthening, or suppressing the immune system in order to fight diseases.
There are 80 different forms of autoimmune illnesses, with rheumatoid arthritis, systemic lupus erythematosus (Lupus), juvenile rheumatoid arthritis, inflammatory bowel arthritis, and psoriatic arthritis being the most common. These autoimmune diseases affect different body organs such as joints, muscles, skin, red blood cells, blood vessels, connective tissues, and endocrine glands. Immunology drugs are one of the preferable choice of immunotherapy that is used by several oncologists as they provide long-lasting affect by activating the immune system to identify cancerous cells and kill them through the natural process & improve the quality of survival.
Market Dynamics
One of the primary factors driving the global immunology market expansion is the high frequency of autoimmune illnesses such as rheumatoid arthritis, systemic lupus erythematosus (Lupus), juvenile rheumatoid arthritis, inflammatory bowel arthritis, Psoriatic arthritis, and others. According to a research from the National Institutes of Health, up to 23.5 million Americans (almost 7% of the population) had an autoimmune disease in 2017, therefore increasing the patient pool which will ultimately boost the market.
Key features of the study:
- This report provides in-depth analysis of the global immunology market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global immunology market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies.
- Key companies covered as a part of this study include AbbVie Inc., Janssen Global Services, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and Allergan plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global immunology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immunology market
Detailed Segmentation:
- Global Immunology Market, By Drug Class:
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- Global Immunology Market, By Disease Indication:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- Global Immunology Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Immunology Market, By Region:
- North America
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Monoclonal Antibody (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
- By Disease Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Prophylaxis of Organ Rejection
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AbbVie Inc.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Janssen Global Services,
- Johnson & Johnson
- Hoffmann-La Roche Ltd.
- Amgen Inc.
- Pfizer Inc.
- Novartis
- Astellas
- Bristol-Myers Squibb Company
- Merck Sharp & Dohme Corp.
- UCB SA
- Allergan plc.
“*” marked represents similar segmentation in other categories in the respective section.
